𝔖 Bobbio Scriptorium

✦ LIBER ✦

The Australia antigen and role of the late Philadelphia general hospital in reducing post-transfusion hepatitis and sequelae

✍ Scribed by John R. Senior; W. Thomas London; Alton I. Sutnick

Book ID: 102243298
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 82 KB
Volume: 54
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.24593

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevention of post-transfusion hepatitis

Prevention of post-transfusion hepatitis. Role of sensitive hepatitis B antigen screening tests, source of blood and volume of transfusion: Koretz RL, Gitnick GL with the assistance of Mitchell JE, Damus K, Ritman SG, Golub L, Kash PL: Am J Med 59: 754–760, 1975

📂 Article 📅 1975 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Role of the different nitric oxide synth

Role of the different nitric oxide synthase (NOS) isoforms in modulating leukocyte-endothelial cell interactions in vivo: S. Laroux, D. Lefer, P. Huang, R. Scalia and M.B. Grisham, LSU Medical Center, Shreveport, LA., Thomas Jefferson University, Philadelphia, PA. and Massachusetts General Hospital, Boston, MA

📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Efficacy of interferon alfa plus ribavir

Efficacy of interferon alfa plus ribavirin versus interferon alone in the treatment of hepatitis B E antigen-positive patients with chronic hepatitis B: Ming-Yang Lai, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei Taiwan; You-Chen Chao, Tri-Service General Hospital, Taipei Taiwan; Tun-Jen Hsiao, Provincial Tao-Yuan Hospital, Tao-Yuan Taiwan; Li-Ying Liao, Taipei Municipal Jen-Ai Hospital, Taipei Taiwan; Sien-Sing Yang, Cathy General Hospital, Taipei Taiwan; K. Arnold Chan, Department of Epidemiology, Harvard School of Public Health, Boston; Ding-Shinn Chen, Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei Taiwan

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

40 kDa peginterferon alfa-2A (PEGASYS®):

40 kDa peginterferon alfa-2A (PEGASYS®): efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B: Graham E Cooksley, Royal Brisbane Hospital, Herston, Queensland Australia; Teerha Piratvisuth, Songklanakarin Hospital, Songkla Thailand; Yuan-Jen Wang, Teipei Veterans General Hospital, Taipei Taiwan; Varocha Mahachai, Chulalongkorn Hospital, Bangkok Thailand; You-Chen Chao, Tri Service General Hosptital, Taipei Taiwan; Tawesak Tanwandee, Siriraj Hospital, Bangkok Thailand; Anuchit Chutaputti, Pramongkutklao Hospital, Bangkok Thailand; Wen Yu Chang, Kaohsiung University Hospital, Kaohsiung Taiwan; Friederike E Zahm, Hoffmann-La Roche Basel Switzerland; Nigel Pluck, Roche Products Ltd, Welwyn Uk

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

The addition of adefovir dipivoxil to la

The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine - preliminary 24 week results: Robert Perillo, Alton L Oschner Clin, New Orleans, LA; Eugene Schiff, Univ of Miami, Miami, FL; Hie-Won L Hann, Jefferson Medical Coll, Philadelphia, PA; Maria Buti, Hosp Valle de Hebron, Barcelona Spain; Simone Strasser, Royal Prince Alfred Hosp, Camperdown, New South Wales Australia; Karen M Watkins, Alison E Moorat, GlaxoSmithKline R&D, Greenford, Middlesex, Uk; Mary A Woesnner, GlasoSmithKline R&D, Research Triangle Park, NC; Pamela Vig, Carol L Brosgart, Gilead Sciences, Foster City, CA; Eric C Bourne, GlaxoSmithKline Virology Lab, Research Triangle Park; Mark C Atkins, GlaxoSmithKline R&D, Greenford, Middlesex Uk

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB